ImmunityBio (NASDAQ:IBRX) Shares Gap Down – Should You Sell?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $6.48, but opened at $6.27. ImmunityBio shares last traded at $6.1450, with a volume of 36,049,692 shares changing hands.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA outlined a clear resubmission path for ANKTIVA (nogapendekin alfa inbakicept) in BCG‑unresponsive papillary NMIBC; ImmunityBio says it will submit additional information within ~30 days after the Type B end‑of‑phase meeting — a concrete regulatory route that materially reduces near‑term binary risk. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA®
• Positive Sentiment: Market reaction: multiple outlets report the stock jumped sharply (mid‑January moves of ~15–20%) after the FDA meeting news, reflecting investor belief that a resubmission could unlock labeled use in an oncology market — the surge has increased liquidity and attention on the ticker. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Analyst/upside notes: HC Wainwright raised long‑range FY2030 EPS estimates materially (A. Maldonado: $0.68 FY2030), and at least one boutique shop reaffirmed a buy with a high $24 price target — these calls support a bullish narrative and can lift sentiment among growth investors.
• Neutral Sentiment: Momentum: coverage highlights the stock hitting fresh highs and an extended multi‑day rally; that’s bullish signal‑wise but increases the chance of short‑term pullbacks as traders take profits. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Bull case discussion: independent bull analyses and commentary outline multiple upside scenarios tied to ANKTIVA label expansion and other pipeline assets — useful for longer‑term thesis but dependent on regulatory and commercial execution. ImmunityBio, Inc. (IBRX): A Bull Case Theory
• Negative Sentiment: Risk/valuation and sell‑side caution: some sector pieces flagged IBRX among names to avoid given extreme momentum and event‑driven volatility; the company still faces clinical, regulatory and commercialization risk, and the recent run has left the share price stretched versus fundamentals. Top 3 Health Care Stocks You May Want To Dump In January

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on IBRX shares. Jefferies Financial Group lifted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Finally, Piper Sandler raised their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

ImmunityBio Stock Up 5.9%

The firm has a market capitalization of $6.76 billion, a PE ratio of -16.79 and a beta of 0.03. The business’s fifty day moving average price is $2.44 and its 200 day moving average price is $2.49.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analyst estimates of $31.88 million. As a group, sell-side analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Slow Capital Inc. acquired a new position in shares of ImmunityBio in the 3rd quarter valued at about $25,000. Envision Financial Planning LLC purchased a new stake in ImmunityBio during the second quarter worth approximately $28,000. Summit X LLC acquired a new stake in shares of ImmunityBio in the second quarter worth $28,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the 2nd quarter valued at $27,000. Finally, Truist Financial Corp purchased a new stake in ImmunityBio during the 3rd quarter worth $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.